Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $80.40.

Several equities research analysts recently weighed in on IMCR shares. Barclays dropped their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. JPMorgan Chase & Co. dropped their target price on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a report on Wednesday, July 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Oppenheimer reissued an “outperform” rating and issued a $89.00 target price (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Finally, Needham & Company LLC dropped their target price on Immunocore from $81.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, September 17th.

Immunocore Trading Down 1.9 %

NASDAQ IMCR opened at $30.50 on Friday. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore has a twelve month low of $29.72 and a twelve month high of $76.98. The firm has a market capitalization of $1.53 billion, a PE ratio of -25.00 and a beta of 0.72. The stock’s 50 day moving average is $35.25 and its 200 day moving average is $44.55.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.25. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The company had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. During the same period in the previous year, the company posted ($0.37) earnings per share. The firm’s revenue was up 26.2% on a year-over-year basis. Research analysts forecast that Immunocore will post -1.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of IMCR. DNB Asset Management AS raised its stake in shares of Immunocore by 35.0% in the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares during the last quarter. NEOS Investment Management LLC purchased a new position in shares of Immunocore in the fourth quarter worth $262,000. XTX Topco Ltd purchased a new position in shares of Immunocore in the second quarter worth $303,000. Tidal Investments LLC purchased a new stake in Immunocore during the first quarter valued at $423,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Immunocore by 69.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after acquiring an additional 2,721 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.